Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13478345 | 0.85 | TSHR (0.38) | PDE4BALDH1A1SLC6A4HTR6 | |
| SCHEMBL23906802 | 0.82 | PTPN1 (0.35) | PDE4BPTPN1DHFRKDM4CNPC1 | |
| SCHEMBL11455772 | 0.82 | CSNK2A1 (0.43) | PDE4BALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL1423902 | 0.79 | NPC1 (0.41) | PDE4BALDH1A1PTPN1NPC1RAB9A | |
| SCHEMBL10071126 | 0.79 | PTPN1 (0.41) | PDE4BALDH1A1SLC6A4PTPN1DHFR | |
| SCHEMBL1423598 | 0.78 | KDM4C (0.37) | PDE4BPTPN1DHFRKDM4C | |
| SCHEMBL11463272 | 0.77 | HPGD (0.44) | PDE4BALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL23906796 | 0.75 | PTPN1 (0.35) | PDE4BPTPN1DHFRKDM4C | |
| SCHEMBL25637155 | 0.75 | PDE4B (0.35) | PDE4BPTPN1DHFRKDM4CNPC1 | |
| SCHEMBL8663836 | 0.74 | SLC6A4 (0.41) | ALDH1A1SLC6A4DHFRKDM4CNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2043646-B1 | (E)-N-{3-(8-Chloro-11H-10-oxa-1-aza- dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-phenyl} -methanesulfonamide as a GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE | LILLY CO ELI (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2043646-B1 | (E)-N-{3-(8-Chloro-11H-10-oxa-1-aza- dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-phenyl} -methanesulfonamide as a GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE | LILLY CO ELI (US) | 2012-05-16 | — | — | EP | disclosed |
| US-8101760-B2 | Glucocorticoid receptor modulator and methods of use | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101760-B2 | Glucocorticoid receptor modulator and methods of use | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101760-B2 | Glucocorticoid receptor modulator and methods of use | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100069425-A1 | GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE | ELI LILLY AND COMPANY (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069425-A1 | GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE | ELI LILLY AND COMPANY (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069425-A1 | GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE | ELI LILLY AND COMPANY (US) | 2010-03-18 | — | — | US | disclosed |
| EP-2043646-A2 | GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE | ELI LILLY AND COMPANY (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008008882-A2 | GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE | ELI LILLY AND COMPANY (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008882-A2 | GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE | ELI LILLY AND COMPANY (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069425-A1 | GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE | NR3C1, NR3C2, MC2R | PDE4B 701/4885ALDH1A1 2595/4885SLC6A4 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.